JP6748704B2 - 抗癌治療剤 - Google Patents

抗癌治療剤 Download PDF

Info

Publication number
JP6748704B2
JP6748704B2 JP2018504078A JP2018504078A JP6748704B2 JP 6748704 B2 JP6748704 B2 JP 6748704B2 JP 2018504078 A JP2018504078 A JP 2018504078A JP 2018504078 A JP2018504078 A JP 2018504078A JP 6748704 B2 JP6748704 B2 JP 6748704B2
Authority
JP
Japan
Prior art keywords
cancer
cell
compounds
aoh39
attributes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018504078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510917A5 (enExample
JP2018510917A (ja
Inventor
ロバート・ジェイ・ヒッキー
リンダ・エイチ・マルカス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RLL LLC
Original Assignee
RLL LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RLL LLC filed Critical RLL LLC
Publication of JP2018510917A publication Critical patent/JP2018510917A/ja
Publication of JP2018510917A5 publication Critical patent/JP2018510917A5/ja
Application granted granted Critical
Publication of JP6748704B2 publication Critical patent/JP6748704B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018504078A 2015-04-10 2016-04-08 抗癌治療剤 Active JP6748704B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/684,259 2015-04-10
US14/684,259 US10420840B2 (en) 2015-04-10 2015-04-10 Anticancer therapeutic agents
PCT/US2016/026619 WO2016164707A1 (en) 2015-04-10 2016-04-08 Anticancer therapeutic agents

Publications (3)

Publication Number Publication Date
JP2018510917A JP2018510917A (ja) 2018-04-19
JP2018510917A5 JP2018510917A5 (enExample) 2019-05-09
JP6748704B2 true JP6748704B2 (ja) 2020-09-02

Family

ID=57072079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504078A Active JP6748704B2 (ja) 2015-04-10 2016-04-08 抗癌治療剤

Country Status (12)

Country Link
US (1) US10420840B2 (enExample)
EP (2) EP3280261B1 (enExample)
JP (1) JP6748704B2 (enExample)
CN (1) CN107404876B (enExample)
AU (1) AU2016245886B2 (enExample)
BR (1) BR122023024844A2 (enExample)
CA (1) CA2978965C (enExample)
ES (1) ES2991018T3 (enExample)
FI (1) FI3878444T3 (enExample)
PL (2) PL3280261T3 (enExample)
PT (1) PT3878444T (enExample)
WO (1) WO2016164707A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119013247A (zh) * 2022-03-07 2024-11-22 希望之城 Pcna抑制剂及其用途
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
EP1874823B1 (en) 2005-04-27 2016-01-13 Indiana University Research and Technology Corporation Cancer specific pcna isoform binding antibodies and uses thereof
CA2612695A1 (en) * 2005-06-27 2007-01-04 Derek J. Hoelz Cspcna isoform modifications and uses thereof
CN101384618A (zh) * 2006-02-17 2009-03-11 印第安纳大学研究及科技有限公司 癌中capcna蛋白-蛋白相互作用的肽基抑制
US20090123487A1 (en) 2007-09-19 2009-05-14 Katia Rothhaar Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA2732737C (en) * 2008-07-24 2019-03-05 Indiana University Research And Technology Corporation Cancer peptide therapeutics
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
US10550070B2 (en) * 2015-09-17 2020-02-04 City Of Hope PCNA inhibitors

Also Published As

Publication number Publication date
AU2016245886A1 (en) 2017-10-12
EP3280261A1 (en) 2018-02-14
FI3878444T3 (fi) 2024-11-19
JP2018510917A (ja) 2018-04-19
EP3280261A4 (en) 2018-12-12
AU2016245886B2 (en) 2020-04-30
CN107404876A (zh) 2017-11-28
US20160296482A1 (en) 2016-10-13
PT3878444T (pt) 2024-11-08
US10420840B2 (en) 2019-09-24
PL3878444T3 (pl) 2025-01-07
CA2978965A1 (en) 2016-10-13
EP3878444A1 (en) 2021-09-15
BR112017019983A2 (pt) 2018-06-19
PL3280261T3 (pl) 2021-09-06
CA2978965C (en) 2023-11-14
EP3878444B1 (en) 2024-10-09
WO2016164707A1 (en) 2016-10-13
EP3280261B1 (en) 2020-12-23
BR122023024844A2 (pt) 2024-01-23
ES2991018T3 (es) 2024-12-02
CN107404876B (zh) 2023-04-14

Similar Documents

Publication Publication Date Title
CN103492369B (zh) 大麻素受体调节剂
AU2017302660B2 (en) Methods of treating prostate cancer
JP2017141269A (ja) 乳がんの処置
JP2002504511A (ja) 癌処置のためのエポチロンの使用
JP2008514726A (ja) ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
JP6748704B2 (ja) 抗癌治療剤
US20130345231A1 (en) Anticancer therapeutic agents
ES2689665T3 (es) Compuestos y métodos para tratar la leucemia
WO2025157284A1 (zh) 包含prmt5抑制剂和化疗剂的药物组合物
WO2025157288A1 (zh) 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物
WO2025157286A1 (zh) 包含prmt5抑制剂和mat2a抑制剂的药物组合物
WO2013138600A1 (en) Radioprotector compounds
EP1968981A2 (en) A method of treating tumors with azaxanthones
JP2003532669A (ja) 高濃度グルタチオンを伴う腫瘍の治療における置換アクリロイルディスタマイシン誘導体の使用
HK40058784A (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
KR20200039756A (ko) MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR 및 MEK/PI3K/mTOR 생물학적 경로의 저해제 및 치료 화합물의 림프 흡수율, 생체이용률 및 용해도를 향상시키는 방법
BR112017019983B1 (pt) Agentes terapêuticos anticâncer
HK1246085B (en) Anticancer therapeutic agents
CN108299390A (zh) 抗肿瘤化合物dcz0415及其制备方法和应用
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
JP2024538726A (ja) 癌の処置に使用するための置換ピリミジン－４（３ｈ）－オン
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
WO2023175615A1 (en) Arts mimetic componds and combinations thereof for treating high-risk neuroblastoma
CN112999236A (zh) 乌本苷用于治疗脑干胶质瘤的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200807

R150 Certificate of patent or registration of utility model

Ref document number: 6748704

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250